Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is -66.23% as of the fiscal period ended Wednesday, December 31, 2025.
Limited history available
ODTX Return on Invested Capital (ROIC) has fewer than three reported periods, so a trend chart would be misleading.
RETURN ON INVESTED CAPITAL (ROIC)
-66.23%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.64%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
-85.80%
vs the sector median at left
Odyssey Therapeutics, Inc.
Market Cap
$870.81M
Return on Invested Capital (ROIC)
-66.23%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$867.03M
Return on Invested Capital (ROIC)
-7.88%
TTM Avg
-13.88%
3Y Avg
-23.54%
5Y Avg
-23.72%
Market Cap
$857.16M
Return on Invested Capital (ROIC)
-16.05%
TTM Avg
-26.23%
3Y Avg
-9.21%
5Y Avg
8.44%
Market Cap
$884.97M
Return on Invested Capital (ROIC)
54.39%
TTM Avg
-47.91%
3Y Avg
-50.01%
5Y Avg
-47.22%
Market Cap
$855.38M
Return on Invested Capital (ROIC)
-94.76%
TTM Avg
-114.06%
3Y Avg
-144.57%
5Y Avg
-144.57%
Market Cap
$887.50M
Return on Invested Capital (ROIC)
11.37%
TTM Avg
4.29%
3Y Avg
-4.73%
5Y Avg
-2.12%
Market Cap
$887.99M
Return on Invested Capital (ROIC)
-25.25%
TTM Avg
-75.69%
3Y Avg
-67.13%
5Y Avg
-61.15%
Market Cap
$853.13M
Return on Invested Capital (ROIC)
18.72%
TTM Avg
24.77%
3Y Avg
-14.92%
5Y Avg
-18.89%
Market Cap
$852.35M
Return on Invested Capital (ROIC)
-163.39%
TTM Avg
-91.89%
3Y Avg
-60.67%
5Y Avg
-60.67%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Odyssey Therapeutics, Inc. (ODTX) | $870.81M | -66.23% | N/A | N/A | N/A |
| SI-BONE, Inc. (SIBN)vs › | $867.03M | -7.88% | -13.88% | -23.54% | -23.72% |
| QuidelOrtho Corporation (QDEL)vs › | $857.16M | -16.05% | -26.23% | -9.21% | 8.44% |
| Arbutus Biopharma Corp (ABUS)vs › | $884.97M | 54.39% | -47.91% | -50.01% | -47.22% |
| Alumis Inc. (ALMS)vs › | $855.38M | -94.76% | -114.06% | -144.57% | -144.57% |
| Bioventus Inc. (BVS)vs › | $887.50M | 11.37% | 4.29% | -4.73% | -2.12% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $887.99M | -25.25% | -75.69% | -67.13% | -61.15% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 18.72% | 24.77% | -14.92% | -18.89% |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | -163.39% | -91.89% | -60.67% | -60.67% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | -23.80% | -58.06% | -39.20% | -32.57% |
ROIC
-66.2%
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | -66.23% |
